IL132853A0 - Combination therapy for modulating the human sexual response - Google Patents

Combination therapy for modulating the human sexual response

Info

Publication number
IL132853A0
IL132853A0 IL13285398A IL13285398A IL132853A0 IL 132853 A0 IL132853 A0 IL 132853A0 IL 13285398 A IL13285398 A IL 13285398A IL 13285398 A IL13285398 A IL 13285398A IL 132853 A0 IL132853 A0 IL 132853A0
Authority
IL
Israel
Prior art keywords
modulating
combination therapy
sexual response
human sexual
human
Prior art date
Application number
IL13285398A
Other languages
English (en)
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen Inc filed Critical Zonagen Inc
Publication of IL132853A0 publication Critical patent/IL132853A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL13285398A 1997-05-19 1998-05-19 Combination therapy for modulating the human sexual response IL132853A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4994797P 1997-05-19 1997-05-19
PCT/US1998/010230 WO1998052569A1 (fr) 1997-05-19 1998-05-19 Therapie combinatoire permettant de moduler la reponse sexuelle chez un patient

Publications (1)

Publication Number Publication Date
IL132853A0 true IL132853A0 (en) 2001-03-19

Family

ID=21962609

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13285398A IL132853A0 (en) 1997-05-19 1998-05-19 Combination therapy for modulating the human sexual response
IL132853A IL132853A (en) 1997-05-19 1999-11-10 Composition for modulating the human sexual response

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL132853A IL132853A (en) 1997-05-19 1999-11-10 Composition for modulating the human sexual response

Country Status (17)

Country Link
EP (1) EP0996447B1 (fr)
JP (2) JP4588809B2 (fr)
KR (1) KR20010012721A (fr)
CN (1) CN1262622A (fr)
AT (1) ATE333279T1 (fr)
AU (1) AU749703B2 (fr)
BR (1) BR9809848A (fr)
CA (1) CA2291160C (fr)
DE (1) DE69835288T2 (fr)
DK (1) DK0996447T3 (fr)
ES (1) ES2270517T3 (fr)
HK (1) HK1028197A1 (fr)
IL (2) IL132853A0 (fr)
NO (1) NO322079B1 (fr)
NZ (1) NZ500921A (fr)
PT (1) PT996447E (fr)
WO (1) WO1998052569A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
CA2251255A1 (fr) * 1998-10-20 2000-04-20 Mcgill University L'utilisation d'agents dopaminergique dans le gestion de dysfonctionnement sexuel
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
CA2366903A1 (fr) * 1999-04-06 2000-10-12 Zonagen, Inc. Methodes permettant de moduler la reponse sexuelle chez les humains
AU5957600A (en) * 1999-07-30 2001-02-19 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
KR20020020536A (ko) * 2000-09-09 2002-03-15 장우영 발기유발제
US20100104624A1 (en) * 2008-06-11 2010-04-29 Peter Langecker Combination therapy using phosphodiesterase inhibitors
US7678078B1 (en) 2008-10-21 2010-03-16 KMG Pharma LLC Intravitreal injection device, system and method
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742054A (en) * 1982-11-23 1988-05-03 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
ZA878182B (en) * 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
FR2680106B1 (fr) * 1991-08-09 1994-03-11 Corbiere Gerome Procede de realisation de formes pharmaceutiques stables d'un derive d'ergoline et les compositions pharmaceutiques ainsi obtenues.
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69534693T2 (de) * 1994-04-22 2006-08-31 Pentech Pharmaceuticals, Inc., Wheeling Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
CN1113757A (zh) * 1994-06-24 1995-12-27 王儒新 一种性功能促进剂及其制备方法
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
JPH09110674A (ja) * 1995-10-16 1997-04-28 Kao Corp 浴用剤組成物

Also Published As

Publication number Publication date
HK1028197A1 (en) 2001-02-09
ATE333279T1 (de) 2006-08-15
ES2270517T3 (es) 2007-04-01
JP2001526686A (ja) 2001-12-18
NO995657L (no) 2000-01-18
EP0996447A1 (fr) 2000-05-03
DE69835288D1 (de) 2006-08-31
JP2009280621A (ja) 2009-12-03
DE69835288T2 (de) 2007-07-19
PT996447E (pt) 2006-12-29
NO995657D0 (no) 1999-11-18
BR9809848A (pt) 2000-06-27
EP0996447B1 (fr) 2006-07-19
WO1998052569A1 (fr) 1998-11-26
CA2291160C (fr) 2008-10-28
AU749703B2 (en) 2002-07-04
AU7498098A (en) 1998-12-11
CN1262622A (zh) 2000-08-09
JP4588809B2 (ja) 2010-12-01
DK0996447T3 (da) 2006-11-13
KR20010012721A (ko) 2001-02-26
NZ500921A (en) 2002-11-26
NO322079B1 (no) 2006-08-14
CA2291160A1 (fr) 1998-11-26
IL132853A (en) 2010-04-15

Similar Documents

Publication Publication Date Title
IL132853A0 (en) Combination therapy for modulating the human sexual response
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
WO2000038730A3 (fr) Techniques permettant d'utiliser un inhibiteur de cyclooxygenase-2 et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques
EA200200208A1 (ru) Синергитическая композиция
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
MY121008A (en) Combination therapy comprising atorvastatin and an antihypertensive agent.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
EP1027054A4 (fr) Apport local d'inhibiteurs de phosphodiesterases, dans le traitement du dysfonctionnement erectile
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
UA41355C2 (uk) Засіб для лікування нейро-сніду
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
UA90077C2 (uk) Антидисритмічні агенти для лікування тазового болю, що призначаються вагінально
MY124786A (en) Bis-arylsulfones
ATE203519T1 (de) Chinolinderivate als antimalariamittel
GB9804886D0 (en) Therapeutic combination
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
CA2055948A1 (fr) Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un antagoniste du calcium pour le traitement de la proteinurie
NO20001548D0 (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat